Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Lillienberg L, Zock JP, Kromhout H, Plana E, Jarvis D, Toren K. A population-based study on welding exposures at work and respiratory symptoms. Ann Occup Hyg. 2008 Mar;52(2):107-15.